{"created":"2023-05-15T11:22:33.399750+00:00","id":1178,"links":{},"metadata":{"_buckets":{"deposit":"2b102bdf-c827-45db-ae3d-a3b65df63543"},"_deposit":{"created_by":1,"id":"1178","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"1178"},"status":"published"},"_oai":{"id":"oai:showa.repo.nii.ac.jp:00001178","sets":["1:54:148:149"]},"author_link":["6291","6290"],"item_10002_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2010-03"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"28","bibliographicPageStart":"17","bibliographicVolumeNumber":"1","bibliographic_titles":[{"bibliographic_title":"昭和大学薬学雑誌"}]}]},"item_10002_description_6":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"不安障害の治療において、従来のベンゾジアゼピン系抗不安薬に加え、セロトニン1A(5-HT1A)部分作動薬や選択的セロトニン再取り込み阻害剤が使用されている。更に、最近臨床応用された抗鬱薬ミルタザピンも5-HT2A/5-HT2C受容体拮抗作用を持つことから、重症な不安障害に対する効果が期待される。これらの薬剤の特性をよく理解し治療を行うことにより、高い治療効果が得られる。","subitem_description_type":"Abstract"}]},"item_10002_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"昭和大学薬学雑誌編集委員会"}]},"item_10002_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1884-7854"}]},"item_10002_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"蜂須, 貢"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"貝谷, 久宜"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-07-26"}],"displaytype":"detail","filename":"P1_17.pdf","filesize":[{"value":"701.2 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"P1_17.pdf","url":"https://showa.repo.nii.ac.jp/record/1178/files/P1_17.pdf"},"version_id":"0b7f55c1-5673-4ffd-a1a9-1ff0667f6254"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper"}]},"item_title":"抗不安薬の効用と限界","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"抗不安薬の効用と限界"}]},"item_type_id":"10002","owner":"1","path":["149"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-06-22"},"publish_date":"2018-06-22","publish_status":"0","recid":"1178","relation_version_is_last":true,"title":["抗不安薬の効用と限界"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T12:52:06.422193+00:00"}